NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders

참고문헌 (137)

1. Saxena, M., "NOD-like receptors : master regulators of inflam mation and cancer", Front. Immunol, 5, pp.327~ (2014)
2. Kufer, T. A., "NLR functions beyond pathogen recognition", Nat. Immunol, 12, pp.121~128 (2011)
3. Jo, E. -K., "Molecular mechanisms regulating NLRP3 inflammasome activation", Cell Mol. Immunol, 13, pp.148~159 (2016)
4. Voet, S., "Inflammasomes in neuroin f lammatory and neurodegenerative diseases", EMBO Mol. Med, 11, pp.e10248~ (2019)
5. Olcum, M., "Inhibitory effects of phytochemicals on NLRP3 inflammasome activation: a review", Phytomedicine, 75, pp.153238~ (2020)
6. Zheng, D., "Inflammasome activation and regulation : toward a better understanding of complex mechanisms", Cell Discov, 6, pp.36~ (2020)
7. Py, B. F., "Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity", Mol. Cell, 49, pp.331~338 (2013)
8. Han, S., "Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase", J. Biol. Chem, 290, pp.18124~18133 (2015)
9. Song, H., "The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3", Nat. Commun, 7, pp.13727~ (2016)
10. Yan, Y., "Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome", Cell, 160, pp.62~73 (2015)
11. Song, N., "NLRP3 phosphorylation is an essential priming event for inflammasome activation", Mol. Cell, 68, pp.185~197 (2017)
12. Zhang, Z., "Protein kinase D at the Golgi controls NLRP3 inflammasome activation", J. Exp. Med, 214, pp.2671~2693 (2017)
13. Spalinger, M. R., "NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22", J. Clin. Invest, 126, pp.1783~1800 (2016)
14. Stutz, A., "NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain", J. Exp. Med, 214, pp.1725~1736 (2017)
15. Arioz, B. I., "The role of melatonin on NLRP3inflammasome activation in diseases", Antioxidants (Basel), 10, pp.1020~ (2021)
16. Cao, S. S., "Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease", Antioxid. Redox Signal, 21, pp.396~413 (2014)
17. Elliott, E. I., "Initiation and perpetuation of NLRP3 inflamma some activation and assembly", Immunol. Rev, 265, pp.35~52 (2015)
18. Yang, Y., "Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors", Cell Death Dis, 10, pp.128~ (2019)
19. Zhou, Y., "MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease", Mol. Neurodegener, 11, pp.28~ (2016)
20. Wang, Z., "LncRNA MIAT downregulates IL-1β, TNF-ɑ to suppress macro phage inflammation but is suppressed by ATP-induced NLRP3 inflammasome activation", Cell Cycle, 20, pp.194~203 (2021)
21. Brocker, C. N., "Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting", Nat. Commun, 11, pp.5847~ (2020)
22. Lin, Y., "Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ame liorate nonalcoholic steatohepatitis in mice", Theranostics, 11, pp.426~444 (2021)
23. Carpentier, S. J., "The signaling adaptor BCAP inhibits NLRP3 and NLRC4inflammasome activation in macrophages through interactions with Flightless 1", Sci. Signal, 12, pp.eaau0615~ (2019)
24. de Almeida, L., "The PYRIN domain-only protein POP1 inhibits inflamma some assembly and ameliorates inflammatory disease", Immunity, 43, pp.264~276 (2015)
25. Ratsimandresy, R. A., "The PYRIN domain-only protein POP2 inhibits inflammasome priming and activation", Nat. Commun, 8, pp.15556~ (2017)
26. Hu, Y., "Tripartite-motif protein 30 negatively regulates NLRP3 inflamma some activation by modulating reactive oxygen species production", J. Immunol, 185, pp.7699~7705 (2010)
27. Martine, P., "HSP70 is a negative regulator of NLRP3 inflammasome acti vation", Cell Death Dis, 10, pp.256~ (2019)
28. Eren, E., "NLRC3 protein inhibits inflammation by dis rupting NALP3 inflammasome assembly via competition with the adaptor protein ASC for pro-caspase-1 binding", J. Biol. Chem, 292, pp.12691~12701 (2017)
29. Pirzada, R. H., "The roles of the NLRP3 inflammasome in neurodegenerative and metabolic diseases and in relevant advanced ther apeutic interventions", Genes(Basel), 11, pp.131~ (2020)
30. Ahmad, B., "Accelerated NLRP3 inflammasome inhibitory peptide design using a recurrent neural network model and mole cular dynamics simulations", Comput Struct. Biotechnol. J, 21, pp.4825~4835 (2023)
31. Bai, R., "The role of NLRP3 inflammasome in cerebrovascular diseases pathology and possible therapeutic targets", ASN Neuro, 13, pp.17590914211018100~ (2021)
32. Wu, K. K. L., "The APPL1-Rab5 axis restricts NLRP3 inflammasome activation through early endosomal-dependent mitophagy in macrophages", Nat. Com mun, 12, pp.6637~ (2021)
33. Ravaut, G., "Monounsaturated fatty acids in obesity-related inflammation", Int. J. Mol. Sci, 22, pp.330~ (2020)
34. Giordano, A., "Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis", J. Lipid Res, 54, pp.2423~2436 (2013)
35. Nishimura, S., "CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity", Nat. Med, 15, pp.914~920 (2009)
36. Wani, K., "Role of NLRP3inflammasome activation in obesity-mediated metabolic disorders", Int. J. Environ. Res. Public Health, 18, pp.511~ (2021)
37. Swanson, K. V., "The NLRP3 inflammasome: molecular activation and regulation to therapeutics", Nat. Rev. Immunol, 19, pp.477~489 (2019)
38. Kursawe, R., "A role of the inflammasome in the low storage capacity of the abdominal subcutaneous adipose tissue in obese adolescents", Diabetes, 65, pp.610~618 (2016)
39. Vandanmagsar, B., "The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance", Nat. Med, 17, pp.179~188 (2011)
40. Saklayen, M. G., "The global epidemic of the metabolic syndrome", Curr. Hypertens. Rep, 20, pp.12~ (2018)
41. Goossens, G. H., "Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans", Mol. Immunol, 50, pp.142~149 (2012)
42. Xia, M., "Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin", Am. J. Pathol, 184, pp.1617~1628 (2014)
43. Legrand-Poels, S., "Free fatty acids as modulators of the NLRP3 inflamma some in obesity", type 2 diabetes, 2014, pp.92, 131~141
44. Wen, H., "Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling", Nat. Immunol, 12, pp.408~415 (2011)
45. Unamuno, X., "NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling", Cell Mol. Immunol, 18, pp.1045~1057 (2021)
46. Tang, Y., "C-reactive protein and ageing", Clin. Exp. Pharm. Physiol, 44, pp.9~14 (2017)
47. Finucane, O. M., "Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity", Diabetes, 64, pp.2116~2128 (2015)
48. López-Reyes, A., "NLRP3 inflammasome : the stormy link between obesity and COVID-19", Front Immunol, 11, pp.570251~ (2020)
49. Bhatraju, P. K., "Covid-19 in Critically Ill Patients in the Seattle Region-Case Series", N. Engl. J. Med, 382, pp.2012~2022 (2020)
50. Simonnet, A., "High prevalence of obesity in severe acute respiratory syn drome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation", Obesity (Silver Spring), 28, pp.1195~1199 (2020)
51. "Diabetes" (2023)[URL]
52. Ahechu, P., "NLRP3 inflammasome : a possible link between obesity associated low-grade chronic inflammation and colorectal cancer development", Front Immunol, 9, pp.2918~ (2018)
53. Feuerer, M., "Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters", Nat. Med, 15, pp.930~939 (2009)
54. Ziegler, A. N., "Insulin and IGF receptor signalling in neural-stem-cell homeostasis", Nat. Rev. Endocrinol, 11, pp.161~170 (2015)
55. Jager, J., "Interleukin-1beta-induced insulin resistance in adipocytes through down regulation of insulin receptor substrate-1 expression", Endocrinology, 148, pp.241~251 (2007)
56. Spranger, J., "Inflammatory cytokines and the risk to develop type 2 dia betes : results of the prospective population-based European Prospective Investigation into Cancer and Nutrition(EPIC)-Potsdam Study", Diabetes, 52, pp.812~817 (2003)
57. Stienstra, R., "Inflammasome is a central player in the induction of obesity and insulin resistance", Proc. Natl. Acad. Sci, 108, pp.15324~15329 (2011)
58. "Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems vol. 8", pp.1~90 (2018), Nature Pub lishing Group
59. "Cardiovascular diseases (CVDs)" (2021)[URL]
60. Krishnan, S. M., "IL-1β and IL 18: inflammatory markers or mediators of hypertension?", Br. J. Pharm, 171, pp.5589~5602 (2014)
61. Qi, J., "NF-κB blockade in hypothalamic paraventricular nucleus inhibits high-salt-induced hypertension through NLRP3 and Caspase-1", Cardiovasc. Toxicol, 16, pp.345~354 (2016)
62. Gan, W., "The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation", Biochim Biophys. Acta Mol. Basis Dis, 1864, pp.1~10 (2018)
63. Su, Q., "Inhibition of reactive oxygen species in hypothalamic para ventricular nucleus attenuates the renin-angiotensin system and proin f lammatory cytokines in hypertension", Toxicol. Appl. Pharm, 276, pp.115~120 (2014)
64. Zhaolin, Z., "Role of pyroptosis in cardiovas cular disease", Cell Prolif, 52, pp.e12563~ (2019)
65. Hoseini, Z., "NLRP3 inflammasome : Its regulation and involvement in atherosclerosis", J. Cell Physiol, 233, pp.2116~2132 (2018)
66. Libby, P., "Atherosclerosis", Nat. Rev. Dis. Prim, 5, pp.56~ (2019)
67. Garg, N. J., "Inflammasomes in cardiovascular diseases", Am. J. Cardiovasc Dis, 1, pp.244~254 (2011)
68. Olsen, M. B., "Targeting the inflammasome in cardiovascular disease", JACC Basic Transl. Sci, 7, pp.84~98 (2022)
69. Peng, K., "P2X7R is involved in the progression of atherosclerosis by pro moting NLRP3 inflammasome activation", Int. J. Mol. Med, 35, pp.1179~1188 (2015)
70. Usui, F., "Critical role of caspase-1 in vascular inflammation and develop ment of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice", Biochem Biophys. Res. Commun, 425, pp.162~168 (2012)
71. Abderrazak, A., "Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet", Circulation, 131, pp.1061~1070 (2015)
72. Jhang, J. -J., "The role of Nrf2 in NLRP3 inflammasome activation", Cell Mol. Immunol, 14, pp.1011~1012 (2017)
73. Chen, M., "LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells : implications in endothelial dys function and atherosclerosis", Pharm. Ther, 95, pp.89~100 (2002)
74. Ding, Z., "LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages : implications in atherogenesis", Cardiovasc. Res, 103, pp.619~628 (2014)
75. Sandanger, Ø., "The NLRP3 inflammasome is up-regulated in cardiac f ibroblasts and mediates myocardial ischaemia-reperfusion injury", Cardiovasc. Res, 99, pp.164~174 (2013)
76. Li, L., "Regulatory role of CARD3 in left ventricular remodelling and dys function after myocardial infarction", Basic Res. Cardiol, 110, pp.56~ (2015)
77. Liu, D., "Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases", Basic Res. Cardiol, 113, pp.5~ (2018)
78. Wu, D., "NLRP3(nucleotide oligomerization domain-like receptor family, pyrin domain containing 3)-caspase-1 inflammasome degrades contractile proteins : implications for aortic biomechanical dysfunction and aneurysm and dissection formation", Arterioscler Thromb. Vasc. Biol, 37, pp.694~706 (2017)
79. Divakaran, S., "The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics", J. Am. Coll. Cardiol, 70, pp.2393~2410 (2017)
80. Mao, K., "Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock", Cell Res, 23, pp.201~212 (2013)
81. Pal Singh, S., "Role of Bruton’s tyrosine kinase in B cells and malignancies", Mol. Cancer, 17, pp.57~ (2018)
82. Weber, A. N. R., "Bruton’s Tyrosine Kinase : an emerging key player in innate immunity", Front Immunol, 8, pp.1454~ (2017)
83. Murthy, P., "The NLRP3 inflammasome and bruton’s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation", Biochem Biophys. Res. Commun, 483, pp.230~236 (2017)
84. Qiao, J., "NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis", Haematologica, 103, pp.1568~1576 (2018)
85. Zhang, W., "Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis : the role of NLRP3 inflammasome activation", PLoS One, 9, pp.e107639~ (2014)
86. Zeng, C., "NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy", Redox Biol, 34, pp.101523~ (2020)
87. Audia, J. P., "Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myo cardial infarct size and preservation of ventricular function", Basic Res. Cardiol, 113, pp.32~ (2018)
88. Butts, B., "Effects of exercise on ASC Methylation and IL-1 cytokines in heart failure", Med Sci. Sports Exerc, 50, pp.1757~1766 (2018)
89. Wang, Y., "NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases", Clin. Transl. Med, 10, pp.91~106 (2020)
90. Chan, Y., "Medicinal Plants for Lung Diseases", pp.47~84 (2021), Springer
91. De Nardo, D., "New insights into mechanisms con trolling the NLRP3 inflammasome and its role in lung disease", Am. J. Pathol, 184, pp.42~54 (2014)
92. Broide, D. H., "Cytokines in symptomatic asthma airways", J. Allergy Clin. Immunol, 89, pp.958~967 (1992)
93. Konno, S., "Cytokine concentrations in sputum of asthmatic patients", Int. Arch. Allergy Immunol, 109, pp.73~78 (1996)
94. Yang, W., "NLRP3 inflammasome is essential for the development of chronic obstructive pulmonary disease", Int. J. Clin. Exp. Pathol, 8, pp.13209~13216 (2015)
95. "Global Initiative for Chronic Obstructive Lung Disease- GOLD" (2020)[URL]
96. Yu, Y., "Th1", Th17 cytokine profiles are associated with disease severity and exacerbation frequency in COPD patients, 2020, pp.15, 1287~1299
97. Wang, H., "NLRP3 inflammasome involves in the acute exacerbation of patients with chronic obstructive pulmonary disease", Inflammation, 41, pp.1321~1333 (2018)
98. Nachmias, N., "NLRP3 inflammasome activity is upregulated in an in-vitro model of COPD exacerbation", PLoS One, 14, pp.e0214622~ (2019)
99. Zhang, M. -Y., "Cigarette smoke extract induces pyroptosis in human bron chial epithelial cells through the ROS", NLRP3, Life Sci, pp.2021, 269[DOI]
100. Rodríguez-Alcázar, J. F., "Charcot-Leyden crystals activate the NLRP3inflammasome and cause IL-1β inflammation in human macrophages", J. Immunol, 202, pp.550~558 (2019)
101. Parfenova, O. K., "Follistatin-like proteins : structure, functions and biomedical importance", Biomedicines, 9, pp.999~ (2021)
102. Wang, Y., "FSTL1 aggravates OVA-induced inflammatory responses by activating the NLRP3", IL-1β signaling pathway in mice and macrophages, 2021, pp.70, 777~787
103. Tsai, Y. -M., "Der f1 induces pyroptosis in human bronchial epithelia via the NLRP3 inflammasome", Int. J. Mol. Med, 41, pp.757~764 (2018)
104. Wood, L. G., "Saturated fatty acids, obesity, and the nucleotide oligomer ization domain-like receptor protein 3(NLRP3)inflammasome in asthmatic patients", J. Allergy Clin. Immunol, 143, pp.305~315 (2019)
105. Guo, D., "Association between oral health behavior and chronic diseases among middle-aged and older adults in Beijing, China", BMC Oral. Health, 23, pp.97~ (2023)
106. Park, E., "Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection", Infect. Immun, 82, pp.112~123 (2014)
107. Chen, Y., "NLRP3 regulates alveolar bone loss in ligature-induced period ontitis by promoting osteoclastic differentiation", Cell Prolif, 54, pp.e12973~ (2021)
108. Naglik, J. R., "Candida albicans-epithelial interactions and induction of mucosal innate immunity", Curr. Opin. Microbiol, 40, pp.104~112 (2017)
109. Pizzicannella, J., "Antioxidant ascorbic acid modulates NLRP3 inflammasome in LPS-G treated oral stem cells through NFκB", Caspase-1, Anti oxidants (Basel), pp.2021, 10[DOI]
110. Yamaguchi, N. H., "Smoking, immunity, and DNA damage", Transl. Lung Cancer Res, 8, pp.S3~S6 (2019)
111. Osman, M., "Smoking-aggravated oral candidiasis : Nrf2 pathway dampens NLRP3 inflammasome", J. Cell Mol. Med, 25, pp.9473~9475 (2021)
112. Villani, A. -C., "Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility", Nat. Genet, 41, pp.71~76 (2009)
113. Kastbom, A., "Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis(the Swedish TIRA project)", Rheumatology, 47, pp.415~417 (2008)
114. Pontillo, A., "Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus", Autoimmunity, 45, pp.271~278 (2012)
115. Hitomi, Y., "Associations of functional NLRP3 polymorphisms with sus ceptibility to food-induced anaphylaxis and aspirin-induced asthma", J. Allergy Clin. Immunol, 124, pp.779~785 (2009)
116. Pontillo, A., "A 3’UTR SNP in NLRP3 gene is associated with susceptibility to HIV-1 infection", J. Acquir Immune Defic. Syndr, 54, pp.236~240 (2010)
117. Pontillo, A., "Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil", Autoimmunity, 43, pp.583~589 (2010)
118. Caseley, E. A., "An atypical autoinflammatory disease due to an LRR domain NLRP3 mutation enhancing binding to NEK7", J. Clin. Immunol, 42, pp.158~170 (2022)
119. Jesus, A. A., "Phenotype-genotype analysis of cryopyrin-associated periodic syndromes(CAPS) : description of a rare non-exon 3 and a novel CIAS1 missense mutation", J. Clin. Immunol, 28, pp.134~138 (2008)
120. Zheng, Y., "Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes", Gene, 530, pp.151~154 (2013)
121. Mridha, A. R., "NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice", J. Hepatol, 66, pp.1037~1046 (2017)
122. Csak, T., "Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells", Hepatology, 54, pp.133~144 (2011)
123. Zheng, M., "Impaired NLRP3 inflammasome activation", pyroptosis leads to robust inflammatory cell death via caspase-8, J. Biol. Chem, pp.2020, 295[DOI]
124. Pirzada, R. H., "Modeling structure–activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics", Front. Endocrinol, 14, pp.1084327~ (2023)
125. Fung, S. -Y., "A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence:lessons from other pathogenic viruses", Emerg. Microbes Infect, 9, pp.558~570 (2020)
126. Bonomini, F., "NLRP3 inflammasome modulation by melatonin supplementation in chronic pristane-induced lupus nephritis", Int. J. Mol. Sci, 20, pp.3466~ (2019)
127. Wu, X., "Melatonin alleviates radiation-induced lung injury via regulation of miR-30e", NLRP3 axis, 2019, pp.2019, 4087298~
128. Triantafilou, K., "The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3inflammasome activation", J. Cell Sci, 126, pp.2903~2913 (2013)
129. de Rivero Vaccari, J. P., "P2X4 receptors influence inflammasome activation after spinal cord injury", J. Neurosci, 32, pp.3058~3066 (2012)
130. Yang, F., "NLRP3 deficiency ameliorates neurovascular damage in experi mental ischemic stroke", J. Cereb. Blood Flow. Metab, 34, pp.660~667 (2014)
131. Ruscitti, P., "Monocytes from patients with rheumatoid arthritis and type 2diabetes mellitus display an increased production of interleukin(IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation : a possible implication for therapeutic decision in these patients", Clin. Exp. Immunol, 182, pp.35~44 (2015)
132. Li, F., "Pretreatment of indobufen and aspirin and their combinations with clopidogrel or ticagrelor alleviates inflammasome mediated pyroptosis via inhibiting NF-κB", NLRP3 pathway in ischemic stroke, 2021, pp.16, 835~853
133. Choi, S., "Nlrp3 inflammasome inhibitory peptide for treatment of inflammatory diseases", ~ (2022)
134. Klughammer, B., "A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3inhibitor selnoflast in patients with moderate to severe active ulcerative colitis", Clin. Transl. Med, 13, pp.e1471~ (2023)
135. Bakhshi, S., "MCC950 in the treatment of NLRP3-mediated inflam matory diseases : latest evidence and therapeutic outcomes", Int. Immuno pharmacol, 106, pp.108595~ (2022)
136. Mangan, M. S. J., "Targeting the NLRP3 inflammasome in inflammatory diseases", Nat. Rev. Drug Discov, 17, pp.588~606 (2018)
137. Nelson, B. E., "First in human phase I study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors", JCO, 41, pp.e14584~e14584 (2023)

관련 논문AI추천